首页> 外文期刊>International Journal of Health Sciences >Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCVrelated
【24h】

Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCVrelated

机译:评估HBV和HCV相关的增殖标志物Ki-67和p53蛋白的表达

获取原文
           

摘要

Background: Chronic HBV and HCV infections are the major risk factors for the development of HCC through a multisteppathway that involves viral and non-viral dependent pathophysiological steps. Hepatic expression of the nuclear proliferativemarker ki-67 and the p53 oncoprotein were found to be associated with poor outcome. So, the present study was done to evaluatethe changes in expression of Ki-67 and p53 oncoprotein, and to determine p53 gene mutation in HBV/HCV-related HCC Egyptianpatients.Methods: Eight HBV-and 22 HCV-positive HCC cases have been examined for the presence of p53 mutation byimmunohistochemistry (IHC) and single-strand conformation polymorphism (SSCP), followed by direct DNA sequencing. HCVwere genotyped by LiPA-II.Results: Our results have shown that the proliferative marker ki-67 LI and p53 were highly expressed and signi?cantly related totumor grade in the Egyptian HCC cases (p0.05). Also, p53 mutation was found in 16 HCC cases by IHC and in 14 HCC casesby SSCP, only 11 patients showed p53 mutation by sequencing. The highest mutation rate was scored for exon 7 (7 mutations)at codon 249; 4 out of 8 (50%) of HBV-related HCC cases and 3 out of 22 (13.6%) of HCV-related HCC cases, followed by exon5 (3 mutations) at codons 133, 146, 176 in HCV-related HCC cases, then exon 8 at codon 275 in HCV-related HCC cases. Theconcordance between the IHC and sequencing analysis was 69%.Conclusion: The present study demonstrates the association between the proliferative marker ki-67 and p53 expression with thetumor grade of Egyptian HBV/HCV-related HCC cases. Our results also support the hypothesis that p53 mutations are rather alate event in the carcinogenesis. Also, they suggest that the ?nal steps of hepatocarcinogenesis are common and independent ofthe aetiology of the viral infection.
机译:背景:慢性HBV和HCV感染是通过涉及病毒和非病毒依赖性病理生理学步骤的多步途径发展HCC的主要危险因素。发现肝增殖核标志物ki-67和p53癌蛋白的表达与预后不良有关。因此,本研究旨在评估HBV / HCV相关的HCC埃及患者中Ki-67和p53癌蛋白表达的变化,并确定p53基因突变。方法:检查了8例HBV和22例HCV阳性的HCC患者通过免疫组织化学(IHC)和单链构象多态性(SSCP)检测p53突变的存在,然后进行直接DNA测序。结果:我们的结果表明,在埃及HCC病例中,增殖标志物ki-67 LI和p53高表达,并且与肿瘤等级显着相关(p <0.05)。此外,通过IHC在16例HCC患者中发现了p53突变,通过SSCP在14例HCC患者中发现了p53突变,只有11例患者通过测序显示出p53突变。密码子249的外显子7(7个突变)得分最高。在HBV相关HCC病例中占8(50%)的4个,在HCV相关HCC病例中占22(13.6%)的3个,其次是HCV相关HCC病例中第133、146、176位密码子的第5外显子,然后是与HCV相关的HCC病例第275位密码子的第8外显子。 IHC与测序分析之间的一致性为69%。结论:本研究证明了增殖标志物ki-67和p53表达与埃及HBV / HCV相关的HCC病例的肿瘤分级之间的相关性。我们的结果也支持以下假设:p53突变是致癌作用中的晚期事件。同样,他们提示肝癌的最终形成步骤很常见,并且与病毒感染的病因无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号